# Cabaletta Bio Inc. (CABA) fundamentals

Data as of 2026-11-10. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $1.45, market value $313 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Cabaletta Bio Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 1.1×**. The shares trade at 1.1× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -52.0%** (5-yr avg -146.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -149.8%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 10.3%**. Earnings per share rose 10.3%.

## Financial health
- **Current ratio: 2.77** (quick 2.77). Current assets cover the next year's liabilities 2.77 times.

## Dividends
- **Dividend: none**. Cabaletta Bio Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -41.2%** (YTD -31.5%, 3-mo -46.4%). The shares are down 41.2% over twelve months including dividends.
- **From 52-week high: -65.7%** (22.9% above the low). Trading 66% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): 1.94** (volatility 83%). Beta of 1.94 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CABA · Page: https://foliofundamentals.com/stocks/caba

Not investment advice.